NASDAQ:ABEO Abeona Therapeutics (ABEO) Stock Price, News & Analysis → get a piece of the profit from this land (From True Market Insiders) (Ad) Free ABEO Stock Alerts $4.40 -0.20 (-4.35%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$4.40▼$4.6250-Day Range$3.17▼$8.6352-Week Range$2.83▼$9.01Volume523,022 shsAverage Volume1.45 million shsMarket Capitalization$120.34 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Abeona Therapeutics alerts: Email Address Abeona Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside377.3% Upside$21.00 Price TargetShort InterestBearish12.94% of Float Sold ShortDividend StrengthN/ASustainability-1.03Upright™ Environmental ScoreNews Sentiment-0.15Based on 10 Articles This WeekInsider TradingAcquiring Shares$102,237 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.14) to ($1.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.09 out of 5 starsMedical Sector173rd out of 921 stocksPharmaceutical Preparations Industry70th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingAbeona Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAbeona Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Abeona Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.94% of the float of Abeona Therapeutics has been sold short.Short Interest Ratio / Days to CoverAbeona Therapeutics has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Abeona Therapeutics has recently increased by 62.62%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAbeona Therapeutics does not currently pay a dividend.Dividend GrowthAbeona Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAbeona Therapeutics has received a 69.10% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases ", "Clinical research services for genetic diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Abeona Therapeutics is -1.03. Previous Next 2.1 News and Social Media Coverage News SentimentAbeona Therapeutics has a news sentiment score of -0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Abeona Therapeutics this week, compared to 2 articles on an average week.Search Interest21 people have searched for ABEO on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat Follows9 people have added Abeona Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Abeona Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $102,237.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.30% of the stock of Abeona Therapeutics is held by insiders.Percentage Held by Institutions80.56% of the stock of Abeona Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Abeona Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Abeona Therapeutics are expected to grow in the coming year, from ($2.14) to ($1.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Abeona Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Abeona Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Abeona Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market Insidersget a piece of the profit from this land This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024. About Abeona Therapeutics Stock (NASDAQ:ABEO)Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Read More ABEO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABEO Stock News HeadlinesApril 30, 2024 | insidertrades.comAbeona Therapeutics Inc (NASDAQ:ABEO) Director Buys $24,764.00 in StockApril 27, 2024 | insidertrades.comInsider Buying: Abeona Therapeutics Inc (NASDAQ:ABEO) CFO Acquires 5,608 Shares of StockApril 27, 2024 | insidertrades.comAbeona Therapeutics Inc (NASDAQ:ABEO) SVP Brendan M. O'malley Acquires 8,600 SharesMay 18 at 4:56 AM | americanbankingnews.comAbeona Therapeutics (NASDAQ:ABEO) Price Target Cut to $21.00May 16 at 8:45 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEOMay 16 at 10:19 AM | finance.yahoo.comQ1 2024 Abeona Therapeutics Inc Earnings CallMay 16 at 10:19 AM | finance.yahoo.comAbeona Therapeutics Inc (ABEO) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...May 15, 2024 | washingtonpost.comAbeona Therapeutics: Q1 Earnings SnapshotMay 15, 2024 | investorplace.comABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q1 2024May 15, 2024 | globenewswire.comAbeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate ProgressMay 12, 2024 | americanbankingnews.comShort Interest in Abeona Therapeutics Inc (NASDAQ:ABEO) Expands By 62.6%May 7, 2024 | globenewswire.comAbeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 6, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEOMay 3, 2024 | marketwatch.comAbeona Therapeutics Shares Rise After Underwritten Offering Gets PricedMay 3, 2024 | markets.businessinsider.comAbeona Prices Offering Of $75 Mln Common Stock, WarrantsMay 3, 2024 | finance.yahoo.comAbeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsMay 2, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of InvestorsMay 1, 2024 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of InvestorsApril 29, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Announces Investigation of Abeona Therapeutics Inc. (ABEO) on Behalf of InvestorsApril 25, 2024 | finance.yahoo.comABEO: Receives CRL Based on Need for More CMC Information…April 23, 2024 | seekingalpha.comAbeona Therapeutics Tanks On CRL From The FDA, But All Hope Is Not LostApril 23, 2024 | finanznachrichten.deAbeona Therapeutics Inc.: Abeona Therapeutics Provides Regulatory Update on Pz-celApril 23, 2024 | msn.comFDA Rejects Approval Of Abeona Therapeutics' Skin Disorder Treatment, Shares SinkApril 23, 2024 | investorplace.comWhy Is Abeona Therapeutics (ABEO) Stock Down 45% Today?April 22, 2024 | marketwatch.comAbeona Therapeutics Shares Down 53% After FDA Complete Response LetterSee More Headlines Receive ABEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today5/18/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ABEO Previous SymbolOTCMKTS:ACCP CUSIPN/A CIK318306 Webwww.abeonatherapeutics.com Phone214-665-9495Fax214-905-5101EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$21.00 Low Stock Price Target$21.00 Potential Upside/Downside+377.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,190,000.00 Net MarginsN/A Pretax Margin-2,190.26% Return on Equity-543.60% Return on Assets-78.51% Debt Debt-to-Equity RatioN/A Current Ratio5.61 Quick Ratio4.15 Sales & Book Value Annual Sales$3.50 million Price / Sales34.38 Cash FlowN/A Price / Cash FlowN/A Book Value($0.32) per share Price / Book-13.75Miscellaneous Outstanding Shares27,350,000Free Float25,905,000Market Cap$120.34 million OptionableOptionable Beta1.59 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Steven H. Rouhandeh (Age 61)Exec. Chairman Dr. Timothy J. Miller (Age 46)Pres, Chief Scientific Officer & Director Mr. Jeffrey Blaine Davis (Age 55)Chief Operating Officer Mr. Carsten Thiel (Age 54)Chief Exec. Officer Mr. Stephen B. Thompson (Age 64)Sr. VP of Fin. and Admin., Chief Accounting Officer, Sec. & Treasurer Key CompetitorsAmylyx PharmaceuticalsNASDAQ:AMLXCoya TherapeuticsNASDAQ:COYAFibroGenNASDAQ:FGENAllakosNASDAQ:ALLKVistagen TherapeuticsNASDAQ:VTGNView All CompetitorsInsiders & InstitutionsWestern Standard LLCBought 553,377 shares on 5/17/2024Ownership: 4.978%Acadian Asset Management LLCBought 12,634 shares on 5/10/2024Ownership: 0.046%Faith L CharlesBought 7,550 shares on 4/26/2024Total: $24,764.00 ($3.28/share)Vishwas SeshadriBought 10,000 shares on 4/25/2024Total: $32,000.00 ($3.20/share)Joseph Walter VazzanoBought 5,608 shares on 4/25/2024Total: $17,609.12 ($3.14/share)View All Insider TransactionsView All Institutional Transactions ABEO Stock Analysis - Frequently Asked Questions Should I buy or sell Abeona Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Abeona Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ABEO shares. View ABEO analyst ratings or view top-rated stocks. What is Abeona Therapeutics' stock price target for 2024? 1 Wall Street analysts have issued 12-month price objectives for Abeona Therapeutics' shares. Their ABEO share price targets range from $21.00 to $21.00. On average, they anticipate the company's share price to reach $21.00 in the next twelve months. This suggests a possible upside of 377.3% from the stock's current price. View analysts price targets for ABEO or view top-rated stocks among Wall Street analysts. How have ABEO shares performed in 2024? Abeona Therapeutics' stock was trading at $5.01 at the beginning of the year. Since then, ABEO shares have decreased by 12.2% and is now trading at $4.40. View the best growth stocks for 2024 here. When is Abeona Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our ABEO earnings forecast. How were Abeona Therapeutics' earnings last quarter? Abeona Therapeutics Inc (NASDAQ:ABEO) issued its quarterly earnings results on Monday, March, 18th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $0.13. What ETFs hold Abeona Therapeutics' stock? ETFs with the largest weight of Abeona Therapeutics (NASDAQ:ABEO) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).Simplify Propel Opportunities ETF (SURI). When did Abeona Therapeutics' stock split? Shares of Abeona Therapeutics reverse split on Tuesday, July 5th 2022. The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Abeona Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Abeona Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Sangamo Therapeutics (SGMO), Energy Transfer (ET), Sorrento Therapeutics (SRNE), Micron Technology (MU), TherapeuticsMD (TXMD), VBI Vaccines (VBIV) and Advanced Micro Devices (AMD). Who are Abeona Therapeutics' major shareholders? Abeona Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Western Standard LLC (4.98%), Acadian Asset Management LLC (0.05%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brendan M O'malley, Christine Berni Silverstein, Edward Carr, Faith L Charles, Joseph Walter Vazzano, Mark Alvino, Michael Amoroso, Todd Wider and Vishwas Seshadri. View institutional ownership trends. How do I buy shares of Abeona Therapeutics? Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ABEO) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaDems have chosen Biden replacement?Paradigm PressExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.